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Ophthalmologic findings in individuals with the acquired immuno
deficiency syndrome (AIDS) are fairly common. A noninfectious
microvasculopathy of the retina is the most frequent manifestation.
Cytomegalovirus (CMV) retinitis is the opportunistic infection most
likely to cause visual loss and must be differentiated from toxoplas
mosis or herpetic retinitis. Ganciclovi, foscarnet, and cidofovir are
the agents available to slow the progression of CMVretinitis, but they
have significant toxicities.
Scope of the problem
Although Hawaii is a relatively small state, the annual rate of
acquired immunodeficiency syndrome (AIDS) of 16.7 per 100,000
people placed Hawaii at 19th among the 50 states and District of
Columbia in 1996.’ The Hawaii Department ofHealth estimates that
approximately 2,300 to 3,200 individuals infected with human
immunodeficiency virus (HIV) live in the islands.2This represents
0.25 percent of the population or one of every 400 persons.
Over 70% of patients with AIDS can develop ocular manifesta
tions, and 90% of patients have ocular disease at autopsy.3Diseases
of the anterior segment of the eye include: molluscum contagiosum,
Kaposi’s sarcoma, dry eyes, herpes zoster ophthalmicus, herpes
simplex keratitis, and microsporidiosis. The retina and choroid can
show involvement with “HTV retinopathy” (retinal hemorrhages,
microvascular abnormalites, nerve fiber layer infarcts), cytomega
lovirus (CMV), herpes simplex, herpes varicella-zoster, syphilis,
toxoplasmosis, pneumocystis, cryptococcus, mycobacteria, histo
plasmosis, candida, and endogenous bacterial retinitis.4’5Vascular
occlusions are possible.6Loss of visual function on psychophysical
testing without infectious retinopathy has been studied.7 Optic
neuropathy, cranial nerve palsies, orbital lymphoma, and orbital
infections can be seen.
Medications used to treat the HIV patient can result in ocular side
effects. Rifabutin-associated iritis8 and Didanosine related retinal
pigment epithelial atrophy have been reported.9
HIV retinopathy
The most common ophthalmoscopic finding is the microvascular
changes of HIV retinopathy. The cotton-wool-spots (representing
nerve fiber layer infarcts), hemorrhages, and microvascular changes
do not represent an opportunistic infection. They are usually asymp
tomatic and will resolve spontaneously. For a patient with known
HIV infection, they have no prognostic value and need only to be
distinguished from an infectious lesion.
The differential diagnosis of cotton-wool-spots and hemorrhages
is nonspecific, and includes: HIV retinopathy, diabetes, hyperten
sion, collagen vascular disease, retinal vascular occlusions, carotid
artery disease, anemia, high altitude retinopathy, dysproteinemias,
leukemia, radiation, pancreatitis, and systemic infections.
CMV retinitis
The most common ocular infection and cause for visual loss is
CMV retinitis which can affect up to 30% patients with AIDS.’°
CD4+ T-cell counts are usually below 0.05 x 109L.” Occasionally,
CMV retinitis may be the presenting opportunistic infection. The
patient may present with symptoms of floaters, flashing lights, a
visual field defect, or blurred vision. The retinitis may also be
discovered on a screening ophthalmoscopic examination. Lesions
may be asymptomatic because they are small and in the peripheral
retina, or an individual may not be paying attention to the sight in
each eye separately.
The diagnosis of CMV retinitis is based on the clinical appearance
of a focal necrotizing retinitis There are multiple, granular, white
foci of retinal whitening with areas of confluence often with
associated hemorrhage. The red and white appearance has been
likened to that of a cheese pizza (Figure 1). A small area of retinitis
may resemble a cotton-wool-spot, but a nerve fiber layer infarct will
resolve in time. Untreated CMV retinitis spreads like a brush fire.
Active, expanding borders leave behind atrophic retina and mottled
retinal pigment epithelium.
Treatment of CMV retinitis
Medications against CMV approved by the Federal Drug Admin
istration at this time are ganciclovir, foscarnet, and cidofovir. All
have been shown to effective in slowing the progression of retinitis.
Successfully treated retinitis shows chorioretinal scarring with no
active granular retinal whitening (Figures 2, 3). Fibroglial tissue,
refractile particles, or white plaques can sometimes occur. The
drugs are virostatic and must be taken indefinitely.
Ganciclovir was developed first, and therefore it has had the most
use. This nucleoside analogue is available intravenously, orally, or
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Fig. 1.—Active CMV retinitis and optic neuritis in the left eye of a 39-year-
old man with AIDS. White, necrotizing retinitis with associated hemor
rhage. Note the granularity at the borders.
Fig. 2.—Inactive CMV retinitis with atrophic retina and pigment epithelial
three months following treatment. Same eye as figure 1. Vision remains
20/20, but there is a persistent inferotemporal visual field defect in the left
Fig. 3.—Inactive CMV retinitis with atrophic retina and pigment epithelial
mottling in the inferior periphery of the left eye of a 34-year-old man with
AIDS. Yellow object to the right is a partial view of a ganciclovir implant
in the viteous cavity.
Research Program (HACRP) with participating local ophthalmolo
gists was involved in two of the clinical trials involving oral
ganciclovir (Syntex 1CM 1653 and 1CM 1774). The intravenous and
oral form should be taken daily for maximal efficacy. Bone marrow
suppression is a major side effect. The intravitreal implant involves
an operation to suture a sustained-release device into the vitreous
cavity. The drug diffuses through a polyvinyl alcohol coating and is
effective for five to eight months. Systemic toxicity is avoided, but
there is no treatment outside the eye or prophylaxis for the fellow
eye.
Foscarnet is administered intravenously also on a daily basis.
Infusion times are more lengthy than ganciclovir to avoid the side
effects of renal toxicity and metabolic shifts.
Cidofoviris the most recently available agent. It has the advantage
of having a maintenance schedule of an intravenous infusion once
every two weeks. Probenecid is used to help decrease the nephrotox
icity. Ocular hypotony is possible.
Relapse of CMV retinitis after initial response to an anti-CMV
medication is common and drug testing is measured by median time
to progression (50 days for intravenous ganciclovir’2,93 days for
120 days for cidofovir’4,226 days for the ganciclovir
implant’5).Reinduction with the same drug or switching to another
agent may again slow the retinitis. Combination treatment may be
effective, but the trade-off is an increase in drug toxicities. Addi
tional drugs are under investigation. Physicians in this state through
the HACRP were involved with MSL 109 which is a monoclonal
antibody against CMV. This study was terminated in 1997 due to
preliminary data showing lack of efficacy and possibly increased
mortality.
Retinal detachment is a serious complication of CMV retinitis. In
one study, 24% of patients with CMV retinitis for one year devel
oped a retinal detachment.’6Active retinitis and larger lesions are
associated with a higher risk for detachment. The patient notices an
abrupt shadow and loss of sight. With extensive areas of atrophic
retina, a standard scleral buckling operation is usually not success
ful. Surgical treatment with the techniques of vitrectomy and
silicone oil injection are needed to help reposition the retina and
preserve sight.
Other important causes of retinitis
Toxoplasmosis causes a focal necrotizing retinitis in immuno
competent individuals and can also present in the patient with HIV
infection. Clinically, toxoplasmosis has more inflammation in the
vitreous and less hemorrhage than CMV retinitis. In the
immunocompromised patient, the infection may be more fulminant
making differentiation from CMV more difficult. The distinction is
important because of the different treatment options which include
pyrimethamine, sulfadiazine, clindamycin, folinic acid, and pred
nisone.
Acute retinal necrosis is a severe, rapidly spreading, necrotizing
retinitis with vitritis, occlusive vasculitis, and optic neuritis caused
by herpes zoster or simplex developing in an otherwise healthy
individual. In the patient with AIDS, it may present with no vascular
occlusion and minimal intraocular inflammation. This has been
given the name progressive outer retinal necrosis (PORN).’7The
rapid progression helps distinguish this infection from CMV retini
tis. Prompt treatment with intravenous acyclovir is recommended,
eye.
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but sight can still be abruptly and permanently lost. There is a high
rate of retinal detachment.
Screening
Studies have shown that the risk of CMV is inversely related to the
CD4+ T-cell counts. Some experts have used those counts to
establish the frequency ophthalmologic examinations as follows:
yearly for CD4+ T-cell counts greater than 0.10 x 1O9IL, every 6
months for CD4+ T-cell counts between 0.1 and 0.05 x 109/L, and
every 4 months for CD4+ T-cell counts less than 0.05 x 109L.°
Summary
Ocular manifestations of AIDS are not uncommon in Hawaii.
Most of the conditions mentioned above have been seen in Hono
lulu. The goal of the ophthalmologist is to maintain useful sight in
an illness which has a high mortality. With early diagnosis of ocular
diseases, this has been the case. Improved systemic treatment
including new combinations of anti-HTV medications have pro
longed the lives of many patients with AIDS. The challenge to
preserve sight and decrease the ocular morbidity of AIDS continues
to evolve with novel presentations of known diseases, new condi
tions, and advances in treatment modalities.
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